SCHEMBL398818

SCHEMBL398818

O=C1Cc2ccc(C(=O)O)cc2N1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 3/20 0.66
SMYD3 Q9H7B4 3/20 0.58
CRBN Q96SW2 2/20 0.57
AHR P35869 3/20 0.56
CMA1 P23946 2/20 0.56
HTT P42858 1/20 0.55
EIF2AK2 P19525 1/20 0.54
PDK2 Q15119 1/20 0.48
HDAC6 Q9UBN7 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
GSK3B P49841 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
ALDH1A1 P00352 1/20 0.46
RARB P10826 1/20 0.46
RARG P13631 1/20 0.46
GAA P10253 1/20 0.45
SRD5A2 P31213 1/20 0.45
HSD11B1 P28845 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29713338 1.00 TDP2 (0.66) TDP2SMYD3CRBNAHRCMA1
SCHEMBL30731586 0.88 CRBN (0.69) TDP2SMYD3CRBNAHRCMA1
SCHEMBL28385255 0.87 SRD5A2 (0.53) TDP2SMYD3CRBNHTTALDH1A1
SCHEMBL30760741 0.86 SMYD3 (0.58) TDP2SMYD3CRBNAHRCMA1
SCHEMBL3194345 0.86 SMYD3 (0.58) TDP2SMYD3CRBNAHRCMA1
SCHEMBL688890 0.86 TDP2 (0.61) TDP2SMYD3AHRHTTGAA
SCHEMBL24124675 0.84 AHR (0.59) TDP2SMYD3CRBNAHRCMA1
SCHEMBL14521036 0.84 CRBN (0.60) TDP2SMYD3CRBNAHRCMA1
SCHEMBL1144991 0.84 SMYD3 (0.59) TDP2SMYD3CRBNHTTALDH1A1
Hydrochloric Acid SCHEMBL29528151 0.84 SMYD3 (0.57) TDP2SMYD3CRBNAHRCMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119118901-A Oxindole derivative, preparation method thereof and application thereof in TRPA1 inhibitor direction 中国人民解放军北部战区总医院 2024-12-13 CN claimed
EP-3710427-B1 SYNTHESIS OF A 2-INDOLINONE DERIVATIVE KNOWN AS INTERMEDIATE FOR PREPARING NINTEDANIB FERMION OY (FI) 2023-03-08 EP claimed
EP-3426649-A1 INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Respivert Limited (GB) 2019-01-16 EP claimed
EP-3394048-A1 INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES Respivert Limited (GB) 2018-10-31 EP claimed
WO-2017153748-A1 INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS RESPIVERT LIMITED (GB) 2017-09-14 WO claimed
WO-2017109513-A1 INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES RESPIVERT LIMITED (GB) 2017-06-29 WO claimed
US-7030112-B2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US claimed
EP-0344634-B1 Bicyclic carboxamides, process for their preparation and medicaments containing them BOEHRINGER MANNHEIM GMBH (DE) 1994-03-30 EP claimed
CN-1038640-A Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material BOEHRINGER MANNHEIM GMBH (DE) 1990-01-10 CN claimed
EP-0344634-A1 Bicyclic carboxamides, process for their preparation and medicaments containing them Roche Diagnostics GmbH (DE) 1989-12-06 EP claimed
US-12630487-B2 Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
EP-3939954-B1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE OTSUKA PHARMA CO LTD (JP) 2025-07-23 EP disclosed
WO-2025093060-A1 3-(INDOLAMINO)METHYLENE INDOLINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF 徐诺药业(南京)有限公司 2025-05-08 WO disclosed
CN-119118901-A Oxindole derivative, preparation method thereof and application thereof in TRPA1 inhibitor direction 中国人民解放军北部战区总医院 2024-12-13 CN disclosed
US-20240207246-A1 PHARMACEUTICAL COMPOSITION KYOWA KIRIN CO., LTD. (JP) 2024-06-27 US disclosed
EP-0809631-A1 PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES CATALYTICA, INC. (US) 1997-12-03 EP disclosed
WO-1996023770-A1 PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES CATALYTICA, INC. (US) 1996-08-08 WO disclosed
EP-0344634-B1 Bicyclic carboxamides, process for their preparation and medicaments containing them BOEHRINGER MANNHEIM GMBH (DE) 1994-03-30 EP disclosed
US-5019587-A Anticoagulants BOEHRINGER MANNHEIM GMBH (DE) 1991-05-28 US disclosed
EP-0344634-A1 Bicyclic carboxamides, process for their preparation and medicaments containing them Roche Diagnostics GmbH (DE) 1989-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207246-A1 PHARMACEUTICAL COMPOSITION EGFR, VEGFA, KDR TDP2 4369/4885SMYD3 4826/4885CRBN 2070/4885
US-12630487-B2 Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine AZI2, ALKBH2, MGMT TDP2 1219/4885SMYD3 61/4885CRBN 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.